Procter & Gamble Stock Rises Despite Cost Concerns for Fiscal 2027

Procter & Gamble's stock rose 1.90% to USD 148.71 on the NYSE at 11:25 a.m. ET on October 6, 2026, following an analyst upgrade. Evercore ISI raised its rating to Outperform and set a price target of USD 166.00, 11.64% above the intraday price. The upgrade was based on a higher first-quarter fiscal 2027 organic sales growth estimate of 3%, compared to the 2% consensus.

The company reported fiscal 2026 net sales of USD 87.0 billion, up 3% from the prior year, with organic sales growth of 1%. However, costs are a significant concern, as Procter & Gamble expects a USD 1.4 billion after-tax earnings headwind in fiscal 2027, with first-quarter EPS projected to fall at least 5%. Fiscal 2026 core operating margin declined by 70 basis points.

Despite the cost pressures, analysts remain optimistic. Royal Bank of Canada adjusted its price target to USD 166.00 while maintaining an Outperform rating. MarketBeat reported a Moderate Buy consensus among 23 analysts, with an average target of USD 161.70, 8.74% above the current price. The next test will come with the first-quarter fiscal 2027 earnings webcast scheduled for October 22, 2026.

As of October 6, 2026, Procter & Gamble's stock was trading within a 52-week range of USD 137.62 to USD 167.25, with a market capitalization of USD 353.5 billion. The upcoming earnings report will reveal whether the company can offset cost pressures through productivity and pricing strategies.